Retina

The authors investigated systemic adverse events associated with commercial mydriatics administered during retinopathy of prematurity (ROP) screening

ViGeneron, based in Munich, also received approval for dose escalation in the ongoing phase 1b clinical trial

Investigators reported that the trial demonstrated significant improvements in visual function and retinal structure for patients with optic neuritis

In October, Oxular began a phase 2 trial for its therapeutic candidate OXU-001, for treatment of diabetic macular oedema

Patients with fibromyalgia experienced changes in the macular ganglion cell layer and retinal nerve fiber layer

The RESTORE Study is the follow-up study of the RESCUE and REVERSE studies of lenadogene nolparvovec to treat vision loss from LHON

Investigators emphasised the need for continued efforts to raise awareness and support patients in attending regular screening

Hot topics around the globe, from clinical trials to the solar eclipse

Highlights from the year, courtesy of our colleagues at Ophthalmology Times

Trending topics and milestone stories from our year in ophthalmology

The number of patients with retinal vascular diseases is expected to increase over time due to the aging population and lifestyle changes

Our top 10 print stories highlight the core content concepts we explored this year

Espansione Group's Light Modulation Low-level Light Therapy (LLLT) is used in ophthalmology and dermatology

The European Commission will assess the marketing authorisation for Eydenzelt (reference product Eylea)

The PFS is approved for treatment of neovascular age-related macular degeneration, diabetic macular oedema and macular oedema following retinal vein occlusion

A retrospective study assessed elevated neutrophil-to-lymphocyte ratios and systemic immune-inflammation index levels in patients with different subtypes of DMO

Clinicians must consider redefining the metrics and intention behind functional outcomes, according to experts from the European Association for the Study of Diabetic Eye Complications

Presentation closely resembled mitogen-activated extracellular signal-regulated kinase inhibitor–associated retinopathy

The annual meeting brought fourth announcements and insights from companies in the retina care space

EAB members from Ophthalmology Times Europe, Ophthalmology Times and Modern Retina are presenting in Florence

Breakthrough technologies are raising the ceiling for functional visual outcomes

What to expect from 4 days in the Fortezza de Basso

OCU410ST is indicated for the treatment of ABCA4-associated retinopathies including Stargardt disease, retinitis pigmentosa and cone-rod dystrophy 3 (CORD3)

ARVN001 is indicated for the treatment of uveitic macular oedema and certain other ophthalmic indications

OPUVIZ, previously known as the biosimilar candidate SB15, has been approved for the treatment of nAMD, DME and other retinal diseases

The positive opinion marks a key regulatory step towards the approval of FYB203, which will go by the trade names AHZANTIVE and Baiama in the European Union

The CRL comes in response to a supplemental New Drug Application for Izervay, a treatment for geographic atrophy secondary to age-related macular degeneration

Optical coherence tomography will be in all eye care services by October 2025

HG202, by HuidaGene Therapeutics, is formulated for clinical use in treating neovascular age-related macular degeneration

New analysis brings disease progression and therapeutics into focus